Why the study?
Does intravenous DDAVP reduce blood loss in patients undergoing total hip replacement?
RCT (n=42)
randomized
No
Does intravenous DDAVP reduce blood loss in patients undergoing total hip replacement?
Effect estimate: 36.2% reduction
Absolute Event Rate: 701.4% vs 1099.5%
p-value: p=<0.05
Intravenous administration of DDAVP during surgery significantly reduces blood loss and transfusion requirements in patients undergoing total hip replacement.
To evaluate the effects of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood loss in surgery, we conducted a randomized trial of the drug on 42 patients undergoing total hip replacement. Twenty-two patients were designated to intravenously receive 0.3 μg/kg of DDAVP (DDAVP group), and the rest 20 were to receive a placebo (control group).The drug significantly reduced mean blood loss by 36.2% (from 1099.5±713.8ml in control group to 701.4±263.7ml in DDAVP group) and volume of blood transfused by 39.6% (from 947.5±540.2ml in control group to 572.7±396.8ml in DDAVP group) during surgery. Other parameters such as urinary output, postoperative blood loss and etc were not significantly different in the two groups. There were no untoward effects of DDAVP.We conclude that the intravenous administration of DDAVP during surgery can be recommended to reduce blood loss significantly in the patients undergoing total hip replacement.
No takes yet. Share an insight, caveat, or question.
Matsubara et al. (1989) conducted an RCT in Total hip replacement (n=42). 1-deamino-8-D-arginine vasopressin (DDAVP) vs. Placebo was evaluated on Mean blood loss during surgery (36.2% reduction, p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: